Churchill JDB, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol. 1939;42:269–76.

Article  Google Scholar 

Hellman S, Hellman WR. Oligometastases. J Clin Oncol. 1995;13:8–10.

Article  PubMed  Google Scholar 

Amini A, Vigneau SC, Evans C, et al. American radium society appropriate use criteria for radiation therapy in oligometastatic or oligoprogressive Non-Small cell lung cancer. Int J Radiat Oncol Biol Phys. 2022;112(2):361–75.

Article  PubMed  Google Scholar 

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.20.00818.

Article  PubMed  PubMed Central  Google Scholar 

Chmura SJ, Khushalani NI, Wang W et al. NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022;40(16).

Izmailov T, Ryzhkin S, Borshchev G, Boichuk S, Oligometastatic Disease (OMD). The classification and practical review of prospective trials. Cancers (Basel). 2023;15(21):5234. https://doi.org/10.3390/cancers15215234. PMID: 37958408; PMCID: PMC10648904.

Article  PubMed  Google Scholar 

Fisher B, Fisher ER. Barrier function of lymph nodes. Cancer Sci. 1966;152:1397–8.

Google Scholar 

Salgado R, Corthals C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013;368:842–51.

Article  Google Scholar 

Patel PH, Patel PD, Morgan M, Frisco D. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol R Coll Radiol. 2019;31:824–33.

Article  PubMed  PubMed Central  Google Scholar 

AlGhamdi H, Kunkel DJ, Mounsey K, et al. The road to dissemination: the concept of oligometastases and the barriers for widespread disease. Cancers. 2022;14(8):2046.

Article  PubMed  PubMed Central  Google Scholar 

Lord SJ, Lord BK, O’Driscoll D et al. De Novo and recurrent metastatic breast cancer – a systematic review of population-level changes in survival since 1995. EClinicalMedicine. 2022;44.

BreastCancer.org. Breast cancer facts and statistics. 2025 Mar 29 [cited 2025 Apr 15]. Available from: https://www.breastcancer.org/facts-statistics

Steenbruggen TG, Slagter MH, Ho V et al. Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de Novo metastatic breast cancer. JNCI Cancer. 2021;5(3).

van Ommen-Nijhof A, Steenbruggen TG, Schats W, Wiersma T, Horlings HM, et al. Prognostic factors in patients with oligometastatic breast cancer - a systematic review. Cancer Treat Rev. 2020;91:102114.

Article  PubMed  Google Scholar 

The Faculty of Clinical Oncology of The Royal College of Radiologists. Stereotactic ablative body radiation therapy (SABR): a resource. 2019 Jan [cited 2025 Apr 15]. Available from: https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019-v6.1.0.pdf

Hellman S, Olson R, Harrow S, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys. 2022;114(4):611–6.

Article  Google Scholar 

Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, et al. Stereotactic ablative radiation for oligoprogressive cancers: results of the randomized phase 2 STOP trial. Int J Radiat Oncol Biol Phys. 2025;121(1):28–38. Epub 2024 Aug 19. PMID: 39168356.

Article  PubMed  Google Scholar 

Tang C, Sherry AD, Haymaker C, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol. 2023;9(6):825–34. https://doi.org/10.1001/jamaoncol.2023.0161.

Article  PubMed  PubMed Central  Google Scholar 

Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, et al. Adding Metastasis-Directed therapy to Standard-of-Care systemic therapy for oligometastatic breast cancer (EXTEND): A Multicenter, randomized phase 2 trial. Int J Radiat Oncol Biol Phys. 2025;121(4):885–93. Epub 2024 Oct 30. PMID: 39486645; PMCID: PMC11850186.

Article  PubMed  Google Scholar 

Tsai YJ. Consolidative use of radiotherapy to block (CURB) oligoprogression-interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast. Int J Radiat Oncol Biol Phys. 2021;111:1325–6.

Article  Google Scholar 

David S, Connolly E, Bressel M, Tan J, Hanna GG, Alomran R et al. Stereotactic ablative body radiotherapy for oligoprogressive Estrogen receptor-positive breast cancer (TROG 20.03 AVATAR): a phase II prospective multicenter trial. Int J Radiat Oncol Biol Phys. 2025;2(1).

Tan H, Cheung P, Louie A, Myrehaug S, Niglas M, Atenafu E, Chu W. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol. 2021;160:159–65.

Article  Google Scholar 

Onal C, Guler O, Yildirim B. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast. 2018;42:150–6.

Article  PubMed  Google Scholar 

Kobayashi T. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19(3):218–37.

Article  PubMed  Google Scholar 

Chen JC, Bazan JG, Obeng-Gyasi S. ASO author reflections: surgical management should be considered in patients with de novo stage IV inflammatory breast cancer. Ann Surg Oncol. 2022;29:6689–90.

Article  PubMed  Google Scholar 

Largillier R, Ferrero J, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol. 2008. https://doi.org/10.1093/annonc/mdn424.

Article  PubMed  PubMed Central  Google Scholar 

Hu M, Shao B, Ran R, Li H. Prognostic factors for patients with metastatic breast cancer: a literature review. Transl Cancer Res. 2021. https://doi.org/10.21037/tcr-20-2119.

Article  PubMed  PubMed Central  Google Scholar 

Solomayer E, Diel I, Meyberg G, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000. https://doi.org/10.1023/A:1006308619659.

Article  PubMed  Google Scholar 

Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998. https://doi.org/10.1200/JCO.1998.16.7.2401.

Article  PubMed  Google Scholar 

Milano M, Katz A, Zhong H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;878:86.

Google Scholar 

Weykamp FKL. Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol. 2020;10:987.

Article  PubMed  PubMed Central  Google Scholar 

Thomsen B, Vesprini D, Eshetu A, Detsky J, Larouche J, Maralani P et al. Breast cancer spine metastases treated with stereotactic body radiation therapy: patient outcomes and predictors. J Neurooncol. 2025:409–18.

Milano MT. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol. 2019;131:45–51.

Article  PubMed  Google Scholar 

Franceschini D, Franzese C, Comito T, Ilieva M, Spoto R, Marzo A, et al. Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (SBRT) for medically inoperable lung and liver oligometastases from breast cancer. Radiother Oncol. 2024. https://doi.org/10.1016/j.radonc.2024.110240.

Article  PubMed  Google Scholar 

Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast. 2016;29:11–7.

Article  Google Scholar 

David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, et al. Stereotactic ablative body radiotherapy (SABR) for bone-only oligometastatic breast cancer: a prospective clinical trial. Breast. 2019;43:55–62.

Google Scholar 

Wong Y, Raghavendra AS, Hatzis C, et al. Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. Oncologist. 2019;24(3):313–8.

Article  PubMed  Google Scholar 

Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19:218–37.

Article  PubMed  Google Scholar 

Nagasaki E. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report. Breast Cancer. 2021;28(5):1051–61.

Article  PubMed  Google Scholar 

Milano MT. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–8.

Article  PubMed  Google Scholar 

Yamamoto T, Niibe Y, Aoki M, Shintani T, Yamada K, Kobayashi M, Yamashita H, Ozaki M, Manabe Y, Onishi H, Yahara K, Nishikawa A, Katsui K, Oh RJ, Terahara A, Jingu K. Analyses of the local control of pulmonary oligometastases after stereotactic body radiotherapy and the impact of local control on survival. BMC Cancer. 2020;20(1):997.

Article